Article Per Year (5 Year)
p-Index From 2021 - 2026
0.61
P-Index
This Author published in this journals
All Journal Pharmaceutical Journal of Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan
Wardhani, Dewanti
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
ANALISIS BIAYA MEDIS LANGSUNG PASIEN BPJS BRONKOPNEUMONIA BALITA DI RAWAT INAP RUMAH SAKIT ISLAM SURABAYA ACHMAD YANI Wardhani, Dewanti; Nita, Yunita; Rahem, Abdul
Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 9 No 1 (2024): JIIS
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.36387/jiis.v9i1.1728

Abstract

Bronchopneumonia is a type of disease that attacks the lungs, often occurring in the bronchi and alveoli, which is caused by viruses, bacteria or fungi. Bronchopneumonia is the most frequently diagnosed infectious disease at the Surabaya Achmad Yani Islamic Hospital in 2022. The aim of the research is to determine the real direct medical costs of toddler bronchopneumonia and the components that make up real direct medical costs. The research uses an observational research design. Data collection was carried out in October 2023 by reviewing medical record data of patients who met the inclusion criteria during the period January 2023-March 2023. The research subjects consisted of 172 patients. The research results show that the real direct medical costs for toddler bronchopneumonia based on the perspective of the Surabaya Achmad Yani Islamic Hospital during the period January 2023-March 2023 are IDR. 463,267,781 with an average cost per patient of Rp. 2,693,417. The largest component of real direct medical costs is the component of use of hospital facilities at 34.87% and the component of costs for medicines and consumable medical materials at 34.06%. Cost analysis is very important so that patient treatment costs become more effective and efficient.
Cost-Effectiveness Analysis of The Antibiotic Ampicillin and Cefuroxime for Bronchopneumonia Patients Toddlers at Secondary Hospital in Surabaya Wardhani, Dewanti; Firdaus, Favian Rafif; Yunita, Nita; Abdul, Rahem
Pharmaceutical Journal of Indonesia Vol. 10 No. 2 (2025)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2025.010.02.1

Abstract

Bronchopneumonia is an infectious disease in toddlers that produces high mortality, morbidity, and costs. The research aims to investigate the cost-effectiveness of ampicillin and cefuroxime for treating bronchopneumonia in toddlers. Data was collected retrospectively from medical records and hospital information systems between March 2023 and August 2023. The hospital-based trial was completed in October 2023. Stratified random sampling was employed to gather samples from those who met the inclusion criteria, which included using ampicillin or cefuroxime and having bronchopneumonia symptoms. Therapeutic success was determined by achieving a normal breathing rate within < 3 days, taking into account total direct medical expenses. The study discovered that the average direct medical cost for ampicillin patients is Rp. 2,792,875 ± 454.704, and for cefuroxime patients, Rp. 2.931.682 ± 908.964 per inpatient. The effectiveness of antibiotics showed that ampicillin (98%) surpassed cefuroxime (96%). Ampicillin's average cost-effectiveness ratio (ACER) is Rp. 28,499, which is less than cefuroxime's Rp. 30,538. The findings of calculating the incremental cost-effectiveness ratio (ICER) of ampicillin and cefuroxime are Rp. -69,404. Ampicillin has lower direct medical costs and higher effectiveness than cefuroxime, making it a more cost-effective therapy for bronchopneumonia in toddlers. Cost-effectiveness pharmacoeconomic studies are necessary to analyze therapy options
Cost-Effectiveness Analysis of The Antibiotic Ampicillin and Cefuroxime for Bronchopneumonia Patients Toddlers at Secondary Hospital in Surabaya Wardhani, Dewanti; Firdaus, Favian Rafif; Yunita, Nita; Abdul, Rahem
Pharmaceutical Journal of Indonesia Vol. 10 No. 2 (2025)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2025.010.02.1

Abstract

Bronchopneumonia is an infectious disease in toddlers that produces high mortality, morbidity, and costs. The research aims to investigate the cost-effectiveness of ampicillin and cefuroxime for treating bronchopneumonia in toddlers. Data was collected retrospectively from medical records and hospital information systems between March 2023 and August 2023. The hospital-based trial was completed in October 2023. Stratified random sampling was employed to gather samples from those who met the inclusion criteria, which included using ampicillin or cefuroxime and having bronchopneumonia symptoms. Therapeutic success was determined by achieving a normal breathing rate within < 3 days, taking into account total direct medical expenses. The study discovered that the average direct medical cost for ampicillin patients is Rp. 2,792,875 ± 454.704, and for cefuroxime patients, Rp. 2.931.682 ± 908.964 per inpatient. The effectiveness of antibiotics showed that ampicillin (98%) surpassed cefuroxime (96%). Ampicillin's average cost-effectiveness ratio (ACER) is Rp. 28,499, which is less than cefuroxime's Rp. 30,538. The findings of calculating the incremental cost-effectiveness ratio (ICER) of ampicillin and cefuroxime are Rp. -69,404. Ampicillin has lower direct medical costs and higher effectiveness than cefuroxime, making it a more cost-effective therapy for bronchopneumonia in toddlers. Cost-effectiveness pharmacoeconomic studies are necessary to analyze therapy options
Co-Authors Abdul Rahem, Abdul Abdul, Rahem Firdaus, Favian Rafif Yunita Nita Yunita, Nita